scispace - formally typeset
Search or ask a question
Author

Mary J. Fidler

Other affiliations: Trinity School of Medicine
Bio: Mary J. Fidler is an academic researcher from Rush University Medical Center. The author has contributed to research in topics: Lung cancer & non-small cell lung cancer (NSCLC). The author has an hindex of 21, co-authored 95 publications receiving 5610 citations. Previous affiliations of Mary J. Fidler include Trinity School of Medicine.


Papers
More filters
Journal ArticleDOI
Ezra E.W. Cohen1, Denis Soulières2, Christophe Le Tourneau3, Christophe Le Tourneau4, Christophe Le Tourneau5, José Dinis6, Lisa Licitra7, Myung-Ju Ahn8, Ainara Soria, Jean-Pascal Machiels9, Jean-Pascal Machiels10, Nicolas Mach, Ranee Mehra11, Barbara Burtness12, Pingye Zhang13, Jonathan D. Cheng13, Ramona F. Swaby13, Kevin J. Harrington14, Kevin J. Harrington15, Mirelis Acosta-Rivera, Douglas Adkins, Morteza Aghmesheh, Mario Airoldi, Eduardas Aleknavicius, Yousuf Al-Farhat, Alain Algazi, Salah Almokadem, Anna Alyasova, Jessica Bauman, Marco Benasso, Alfonso Berrocal, Victoria Bray, Barbara Ann Burtness12, F. Caponigro, Ana Castro, Terrence P. Cescon, Kelvin K. W. Chan, Arvind Chaudhry, Bruno Chauffert, Ezra W. Cohen1, Tibor Csoszi, J. de Boer, Jean-Pierre Delord, Andreas Dietz, Charlotte Dupuis, Laurence Digue, Jozsef Erfan, Yolanda Alvarez, Mererid Evans, Mary J. Fidler, Martin David Forster, Signe Friesland, Apar Kishor Ganti, Lionnel Geoffrois, Cliona Grant, Viktor Gruenwald, Kevin J. Harrington15, Thomas K. Hoffmann, Geza Horvai, Arturas Inciura, Raymond Woo-Jun Jang, Petra Jankowska, Antonio Jimeno, Mano Joseph, Alejandro Juarez Ramiro, Boguslawa Karaszewska, Andrzej Kawecki, Ulrich Keilholz, Ulrich Keller, Sung Bae Kim, Judit Kocsis, Nuria Kotecki, Mark F. Kozloff, Julio Lambea, Laszlo Landherr, Yuri Lantsukhay, Sergey Alexandrovich Lazarev, Lip Way Lee, Igor Dmitrievich Lifirenko, Danko Martincic, Oleg Vladmirovhich Matorin, Margaret McGrath, Krzysztof Misiukiewicz, John C. Morris, Fagim Fanisovich Mufazalov, Jiaxin Niu, Devraj Pamoorthy Srinivasan, Pedro Perez Segura, Daniel Rauch, Maria Leonor Ribeiro, Cristina P. Rodriguez, Frederic Rolland, Antonio Russo, Agnes Ruzsa, Frederico Sanches, Sang-Won Shin, Mikhail Shtiveland, Pol Specenier, Eva Szekanecz, Judit Szota, Carla M.L. van Herpen, Hector A. Velez-Cortes, William V. Walsh, Stefan Wilop, Ralph Winterhalder, Marek Z. Wojtukiewicz, Deborah Wong, Dan P. Zandberg 
TL;DR: The clinically meaningful prolongation of overall survival and favourable safety profile of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation of p embrolizUMab as a monotherapy and as part of combination therapy in earlier stages of disease.

984 citations

Journal ArticleDOI
TL;DR: Installing maintenance pembrolizumab in patients with extensive‐stage SCLC after treatment with platinum and etoposide did not appear to improve median PFS compared with the historical data, however, the 1‐year PFS rate of 13% and OS rate of 37% suggest that a subset of patients did benefit from pembrolexumab.

148 citations

Journal ArticleDOI
TL;DR: It is reported that unadjuvanted seasonal influenza vaccination via intratumoral, but not intramuscular, injection converts “cold” tumors to hot, generates systemic CD8+ T cell-mediated antitumor immunity, and sensitizes resistant tumors to checkpoint blockade, and proposes that antipathogen vaccines may be utilized for both infection prevention and repurposing as a cancer immunotherapy.
Abstract: Reprogramming the tumor microenvironment to increase immune-mediated responses is currently of intense interest. Patients with immune-infiltrated “hot” tumors demonstrate higher treatment response rates and improved survival. However, only the minority of tumors are hot, and a limited proportion of patients benefit from immunotherapies. Innovative approaches that make tumors hot can have immediate impact particularly if they repurpose drugs with additional cancer-unrelated benefits. The seasonal influenza vaccine is recommended for all persons over 6 mo without prohibitive contraindications, including most cancer patients. Here, we report that unadjuvanted seasonal influenza vaccination via intratumoral, but not intramuscular, injection converts “cold” tumors to hot, generates systemic CD8+ T cell-mediated antitumor immunity, and sensitizes resistant tumors to checkpoint blockade. Importantly, intratumoral vaccination also provides protection against subsequent active influenza virus lung infection. Surprisingly, a squalene-based adjuvanted vaccine maintains intratumoral regulatory B cells and fails to improve antitumor responses, even while protecting against active influenza virus lung infection. Adjuvant removal, B cell depletion, or IL-10 blockade recovers its antitumor effectiveness. Our findings propose that antipathogen vaccines may be utilized for both infection prevention and repurposing as a cancer immunotherapy.

122 citations

Journal ArticleDOI
TL;DR: Chemo (PF) before surgery improved overall survival (OS) in those patients in most of the randomized trials and in meta-analyses and it was found that those patients with pathologic complete response to the initial treatment did better than those who had no improvement at all.

96 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express PD-L1 as mentioned in this paper.
Abstract: BackgroundPembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non–small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). MethodsIn this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator’s choice of platinum-based chemotherapy. Crossover from the chemotherapy group to the pembrolizumab group was permitted in the event of disease progression. The primary end point, progression-free survival, was assessed by means of blinded, independent, central radiologic review. Secondary end points were overall survival, objective response rate, and safety. ResultsMedi...

7,053 citations

Journal ArticleDOI
TL;DR: This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.
Abstract: Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.

5,777 citations

Journal ArticleDOI
TL;DR: Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer and PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolIZumab.
Abstract: BackgroundWe assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non–small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of the PD-1 ligand 1 (PD-L1) that is associated with the likelihood of clinical benefit. MethodsWe assigned 495 patients receiving pembrolizumab (at a dose of either 2 mg or 10 mg per kilogram of body weight every 3 weeks or 10 mg per kilogram every 2 weeks) to either a training group (182 patients) or a validation group (313 patients). We assessed PD-L1 expression in tumor samples using immunohistochemical analysis, with results reported as the percentage of neoplastic cells with staining for membranous PD-L1 (proportion score). Response was assessed every 9 weeks by central review. ResultsCommon side effects that were attributed to pembrolizumab were fatigue, pruritus, and decreased appetite, with no clear difference according to dose or schedule. Among all ...

4,834 citations

Journal ArticleDOI
TL;DR: Although initially thought to be rare, the incidence rates of renal toxicities might be higher as identified by recent studies, Steroids appear to be effective in treating the immune-related adverse effects noted with these agents.
Abstract: Background: Cancer immunotherapy, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death 1 (PD-1), has revolutionized the tre

3,035 citations